Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

  1. Halwani, A.S.
  2. Panizo, C.
  3. Isufi, I.
  4. Herrera, A.F.
  5. Okada, C.Y.
  6. Cull, E.H.
  7. Kis, B.
  8. Chaves, J.M.
  9. Bartlett, N.L.
  10. Ai, W.
  11. de la Cruz-Merino, L.
  12. Bryan, L.J.
  13. Houot, R.
  14. Linton, K.
  15. Briones, J.
  16. Chau, I.
  17. von Keudell, G.R.
  18. Lu, H.
  19. Yakovich, A.
  20. Chen, M.
  21. Meulen JH, T.
  22. Yurasov, S.
  23. Hsu, F.J.
  24. Flowers, C.R.
Journal:
Leukemia and Lymphoma

ISSN: 1029-2403 1042-8194

Year of publication: 2022

Volume: 63

Issue: 4

Pages: 821-833

Type: Article

DOI: 10.1080/10428194.2021.2010057 GOOGLE SCHOLAR

Sustainable development goals